Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 2/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.30 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684589 | 0.92 | CMA1 (0.33) | ACACBACACACMA1 | |
| SCHEMBL2314667 | 0.84 | CTSG (0.32) | ACACBACACACMA1ALKBH5FTO | |
| SCHEMBL2318315 | 0.83 | CTSG (0.32) | ACACBACACACMA1ALKBH5FTO | |
| SCHEMBL3686129 | 0.81 | NPC1 (0.31) | ACACACMA1 | |
| SCHEMBL3687513 | 0.78 | CMA1 (0.38) | CMA1PKM | |
| SCHEMBL3699071 | 0.77 | CMA1 (0.45) | CMA1ALDH1A1 | |
| SCHEMBL3699074 | 0.77 | CMA1 (0.45) | CMA1ALDH1A1 | |
| SCHEMBL2315759 | 0.77 | CNR1 (0.34) | CMA1ALKBH5FTO | |
| SCHEMBL3701617 | 0.77 | GAA (0.42) | ALDH1A1 | |
| SCHEMBL3695212 | 0.77 | CMA1 (0.35) | CMA1PKMALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | claimed |
| EP-2188277-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009023655-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| US-8377949-B2 | Quinazolinedione chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2188277-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023655-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | CMA1, CTSC, TPSG1 | ACACB 161/4885ACACA 208/4885CMA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.